Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn's disease: results from a long-term extension study

被引：0
|
作者：
D'Haens, G. [1 ]
Laharie, D. [2 ,3 ]
Dulai, P. S. [4 ]
Seibold, F. [5 ]
Siegmund, B. [6 ]
Abraham, B. [7 ,8 ,9 ]
Malter, L. [10 ]
Protic, M. [11 ]
Morris, N. [11 ]
Hozak, R. R. [11 ]
Moses, R. E. [11 ]
Lopes, M. Ugolini [11 ]
Durand, F. [11 ]
Yu, G. [11 ]
Vermeire, S. [12 ]
机构：
[1] Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Hop Haut Leveque, CHU Bordeaux, Serv Hepatogastroenterol, Bordeaux, France
[3] Univ Hosp Bordeaux, Digest Oncol Dept, Bordeaux, France
[4] Univ Calif San Diego, Div Gastroenterol, Los Angeles, CA 90089 USA
[5] Crohn Colitis Zentrum Intesto, Lindenhofspital, Bern, Switzerland
[6] Charite, Med Dept, Div Gastroenterol Infectiol & Rheumatol, Berlin, Germany
[7] Houston Methodist Hosp, Houston Methodist Gastroenterol Associates, Houston, TX USA
[8] Houston Methodist Acad Inst, Dept Med, Houston, TX USA
[9] Weill Cornell Med Coll, Dept Med, New York, NY USA
[10] NYU Langone Hlth, Div Gastroenterol, Dept Med, New York, NY USA
[11] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA
[12] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, KU Leuven, Dept Chron Dis & Metab, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0085
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP046
引用
收藏
页码：i168 / i170
页数：3
相关论文
共 50 条
  • [41] Long-term safety and tolerability of apremilast in patients with moderate to severe psoriasis: Results from the LIBERATE study
    Crowley, Jeffrey
    Langley, Richard
    Zhang, Zuoshun
    Goncalves, Joana
    Paris, Maria
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB259 - AB259
  • [42] Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn′s Disease: A Brazilian Multicentre Real-world Study
    Oleg, Knyazev
    Albina, Lishchinskaya
    Anatoliy, Konoplyannikov
    Anna, Kagramanova
    Nina, Fadeeva
    Dmitriy, Kulakov
    Anait, Babayan
    Mariya, Zvyaglova
    Asfold, Parfenov
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S2 - S2
  • [43] LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN'S DISEASE: A MULTICENTER REAL-LIFE STUDY
    Scribano, M. L.
    Aratari, A.
    Neri, B.
    Bezzio, C.
    Balestrieri, P.
    Falasco, G.
    Camastra, C.
    Pantanella, P.
    Monterubbianesi, R.
    Tullio, A.
    Saibeni, S.
    Papi, C.
    Biancone, L.
    Cosintino, R.
    Faggiani, R.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S129 - S129
  • [44] LONG-TERM EFFECTIVENESS AND SAFETY OF ADALIMUMAB BASED ON CROHN'S DISEASE DURATION: RESULTS FROM THE PYRAMID REGISTRY
    Loftus, Edward V.
    Reinisch, Walter
    Panaccione, Remo
    Berg, Sofie
    Bereswill, Mareike
    Kalabic, Jasmina
    Skup, Martha
    Petersson, Joel H.
    Robinson, Anne M.
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2018, 154 (06) : S403 - S403
  • [45] Long-term effectiveness and safety of adalimumab based on Crohn's disease duration: Results from the PYRAMID registry
    Loftus, E. V., Jr.
    Reinisch, W.
    Panaccione, R.
    Berg, S.
    Bereswill, M.
    Kalabic, J.
    Skup, M.
    Petersson, J.
    Robinson, A. M.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S493 - S494
  • [46] LONG-TERM CUMULATIVE SAFETY USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS
    Sands, Bruce E.
    Hanauer, Stephen B.
    Jairath, Vipul
    Mihaly, Emese
    Vicente, Raquel
    Ott, Elyssa
    Gasink, Christopher
    Miao, Ye
    Ma, Tony
    Marano, Colleen W.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S960 - S961
  • [47] Long-term cumulative safety of ustekinumab in bionaive patients with Crohn's Disease and Ulcerative Colitis
    Danese, S.
    Hanauer, S. B.
    Jairath, V.
    Mihaly, E.
    Lidon, R. Vicente
    Ott, E.
    Gasink, C.
    Miao, Y.
    Ma, T.
    Marano, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I434 - I434
  • [48] Long-term cumulative safety of ustekinumab in bionaive patients with Crohn's Disease and Ulcerative Colitis
    Danese, S.
    Hanauer, S. B.
    Jairath, V.
    Mihaly, E.
    Lidon, R. Vicente
    Ott, E.
    Gasink, C.
    Miao, Y.
    Ma, T.
    Marano, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I434 - I434
  • [49] Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    Papp, K. A.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. -C.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (04) : 844 - 854
  • [50] Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohn's Disease Patients: Results from the IM-UNITI Maintenance Study
    Sands, Bruce
    Gasink, Chris
    Jacobstein, Doug
    Gao, Long Long
    Johanns, Jewel
    Szapary, Philippe
    Colombel, Jean-Frederic
    Targan, Stephan
    Ghosh, Subrata
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S302 - S303
12345